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The Epstein-Barr virus (EBV) proteins latent membrane proteins 1 and 2 (LMP1 and LMP2) are frequently expressed in EBV-
associated lymphoid and epithelial cancers and have complex effects on cell signaling and growth. The effects of these proteins
on epithelial cell growth were assessed in vivo using transgenic mice driven by the keratin 14 promoter (K14). The development
of papillomas and carcinomas was determined in the tumor initiator and promoter model using dimethyl benzanthracene
(DMBA), followed by repeated treatments of 12-O-tetradecanoyl phorbol 13-acetate (TPA). In these assays, LMP1 functioned as
a weak tumor promoter and increased papilloma formation. In contrast, mice expressing LMP2A did not induce or promote
papilloma formation. Transgenic LMP1 mice had slightly increased development of squamous cell carcinoma; however, the de-
velopment of carcinoma was significantly increased in the doubly transgenic mice expressing both LMP1 and LMP2A. DMBA
treatment induces an activating mutation in the Harvey-ras (H-ras61) oncogene, and this mutation was identified in most papil-
lomas and carcinomas although several papillomas and carcinomas in K14-LMP1 and K14-LMP1/LMP2A mice lacked the muta-
tion. Analysis of signaling pathways that are known to be activated by LMP1 and/or LMP2 indicated that all genotypes had high
levels of activated extracellular signal-regulated kinase (ERK) and Stat3 in carcinomas with significantly higher activation in the
doubly transgenic carcinomas. These findings suggest that, in combination, LMP1 and LMP2 contribute to carcinoma progres-
sion and that this may reflect the combined effects of the proteins on activation of multiple signaling pathways. This study is the
first to characterize the effects of LMP2 on tumor initiation and promotion and to identify an effect of the combined expression
of LMP1 and LMP2 on the increase of carcinoma development.
Epstein-Barr virus (EBV) is an important human pathogen thatis closely linked to major malignancies that develop in both
epithelial and lymphoid cells and include nasopharyngeal carci-
noma (NPC), gastric cancer, Hodgkin lymphoma, Burkitt lym-
phoma, and lymphomas that develop in the immunocompro-
mised, including both AIDS and posttransplant lymphomas (38,
54). The EBV latent membrane proteins 1 and 2 (LMP1 and
LMP2) are frequently expressed in these cancers and have pro-
found effects on cellular signaling networks and growth properties
in vitro (31, 37). In epithelial cells, LMP1 and LMP2 have been
shown to affect differentiation, migration, anchorage indepen-
dence, and tumorigenicity.
LMP1 is required for transformation of B lymphocytes by EBV
infection and can transform rodent and human fibroblasts to
form foci and colonies in soft agar and tumors in nude mice (38).
LMP1 functionally resembles a ligand-independent constitutively
active member of the tumor necrosis factor receptor (TNFR) su-
perfamily and binds the same TNFR-associated factors (TRAFs)
as CD40. Using transgenic mice, it was shown that, in vivo, LMP1
can partially substitute for CD40 in activating B cell responses
(51). Similarly to other members of the TNFR family, LMP1 acti-
vates many signaling pathways, including NF-B, PI3K/Akt,
AP-1, Jak/Stat, Jun N-terminal protein kinase (JNK), and the p38
and extracellular signal-regulated kinase (ERK) mitogen-acti-
vated protein kinases (MAPKs) (31, 37, 50). Activation of NF-B
is required for B cell transformation by EBV and its inhibition
results in cell death through apoptosis (2). However, in rodent
fibroblast transformation, activation of NF-B by LMP1 is not
required, whereas activation of both PI3K and ERK is essential
(22). Expression of LMP1 in some epithelial cell lines results in
epithelial/mesenchymal transition (EMT) and a cadherin switch,
an increasingly recognized phenomenon responsible for the me-
tastasis of melanomas, breast, and prostate cancers (46).
Although LMP2 is not strictly required for B cell transforma-
tion, it has major effects on B cell signaling and growth, as it can
both block and substitute for signaling from the B cell receptor
(29, 30). In transgenic mice, where LMP2 is expressed under the
control of the immunoglobulin heavy chain promoter and en-
hancer (Ig-LMP2), LMP2 provides prosurvival signals to allow for
the survival and colonization of aberrant B cells lacking a func-
tional B cell receptor in peripheral lymphoid organs (3, 4). Expres-
sion of LMP2 in epithelial cell lines inhibits differentiation and
induces migration. LMP2 expression also results in transforma-
tion of some epithelial cell lines to anchorage independence and
tumorigenicity through effects on Syk, PI3K/Akt, and Ras activa-
tion (18, 33, 34, 41). LMP1 and LMP2 have also been shown to be
secreted in exosomes, and exposure to LMP1 exosomes induces
activation of ERK and PI3K (11, 26). These potential paracrine
effects may be more apparent in vivo than in in vitro cell cultures.
EBV efficiently infects and transforms B lymphocytes in vitro;
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however, epithelial infection is inefficient and persistent infection
and transformation do not result (55). Thus, many of the proper-
ties of LMP1 and LMP2 on epithelial cells have been identified by
expression of the proteins in cell lines in vitro and their individual
or combined effects have not been tested in vivo. Transgenic mice
are a powerful tool to identify and characterize the transforming
properties of viral and cellular genes in vivo. For example, the
Ig-LMP2 transgenic mice revealed prosurvival signals that were
not apparent in cultured cells (3, 4). Similarly, LMP1 cannot
transform B lymphocytes by itself; however, Ig promoter trans-
genic LMP1 mice do have increased development of B cell lym-
phomas. These lymphomas develop in approximately 50% of el-
derly mice (51). The low penetrance and advanced age suggest that
additional genetic changes occur that synergize with LMP1 to con-
tribute to lymphoma development.
A limited number of studies in epithelial cells in transgenic
mice have shown that LMP1 expressed under the control of the
polyomavirus early promoter resulted in hyperproliferation of the
basal epithelium and in classic initiation-promotion studies
showed enhanced carcinogen-induced papilloma formation (8,
52). In these transgenic mice, LMP1 could partially substitute for
treatment with the tumor promoter, 12-O-tetradecanoyl phorbol
13-acetate (TPA), in the multistage carcinogenesis model. LMP1
transgenic mice with expression controlled by the ED-L2 EBV
early lytic promoter, which is highly active in stratified epithelial
cells, had high levels of LMP1 expression particularly evident in
the ears, where highly inflamed corrosive lesions developed that
could progress to carcinomas (7, 48). Transgenic mice, where ex-
pression of LMP2 was targeted to the basal epithelium using the
K14 keratin promoter, lacked an apparent phenotype on epithelial
cell differentiation or spontaneous cancerous growth (17).
In this study, transgenic mice that express LMP1 and LMP2
using the K14 promoter were evaluated for their ability to func-
tion in tumor initiation, promotion, or progression in classical
skin painting experiments. K14-LMP1 transgenic mice had in-
creased and prolonged development of papillomas after dimethyl
benzanthracene (DMBA) and TPA treatment, indicating that it
functioned as a weak promoter. In contrast, K14-LMP2 mice were
similar to nontransgenic controls. Additionally, the doubly trans-
genic mice developed papillomas comparably to the singly trans-
genic K14-LMP1 mice, indicating the lack of effect of LMP2 on
LMP1-enhanced papilloma formation. Importantly, the develop-
ment of squamous cell carcinoma (SCC) was significantly in-
creased in the doubly transgenic animals. Identification of path-
ways known to be activated by LMP1 and/or LMP2 revealed that
all tumors had high levels of activated ERK and Stat3, with the
highest levels in the doubly transgenic carcinomas. This is the first
analysis of LMP1 and LMP2 expressed in combination in epithe-
lial cells in transgenic mice. These findings indicate that expres-
sion of LMP1 and LMP2 increases susceptibility to tumor devel-
opment.
MATERIALS AND METHODS
Ethics statement. Animals were housed at The University of North Car-
olina at Chapel Hill in facilities accredited by the international Association
for the Assessment and Accreditation of Laboratory Animal Care. All
protocols were approved by University of North Carolina Institutional
Animal Care and Use Committee (under IACUC protocol identification
no. 09-247, 06-244, 03-278), compliant with the United States Public
Health Service Policy on Humane Care and Use of Laboratory Animals,
the Amended Animal Welfare Act of 1985, and the regulations of the
United States Department of Agriculture (USDA) (Animal Welfare As-
surance no. A3410-01; USDA registration no. 55-R-004). This study was
carried out in strict accordance with the recommendations in the Guide
for the Care and Use of Laboratory Animals of the National Institutes of
Health. To minimize suffering, animals were monitored daily and sub-
jected to a maximum of 3 skin biopsies. Mice carrying tumor lesions
reaching 1.3 cm were euthanized.
Generation of transgenic mice. The K14-LMP1 mice were generated
from EBV genomic sequences (169570 to 166620) encoding the LMP1
gene cloned into the BamHI site of pGEM2 (Promega). EcoRI linkers were
added to the HindIII fragment containing the K14 promoter, a gift from
Miroslav Blumenberg of NYU Langone Medical Center, and this frag-
ment was subcloned into the EcoRI site in the multiple cloning site up-
stream of LMP1. The constructs were confirmed by sequencing. The K14-
LMP1 construct was linearized with PvuI and injected into fertilized oocytes
from (C57BL/6  SJL)F1 mice. Founders were crossed initially to BALB/c.
Animals were screened for the presence of the transgene by Southern blot
analysis of tail DNA and hybridization to the XhoI fragment within LMP1
(13) or by PCR with primers 168821R (5=AGAGTCCACCAGTTTTGTTG-
3=) and 169251L (5=ACCTTCTCTGTCCACTTGGA-3=). Transgenic
mice expressing LMP2A (K14-LMP2) were a kind gift from Richard
Longnecker of Northwestern University (17) and genotyped by PCR with
primers LMP2-741R (5=CAGGGGGCCTAGGTACTCTT-3=) and LMP2-
951L (5=GTGCCCAAAATCAGTGACGC-3=). Transgenic mice were
maintained, and DMBA/TPA treatment studies were performed with the
assistance of the Animal Studies Core (University of North Carolina at
Chapel Hill).
DMBA/TPA treatment. The backs of 6- to 8-week-old mice were
shaved and painted once with 100 g of DMBA on one side and acetone as
the vehicle control on the other side. One week later, mice were painted
with TPA twice weekly with 10 nmol of TPA or acetone for 20 weeks. Mice
were shaved every 2 weeks and monitored for benign growths (papillo-
mas) and malignant lesions (carcinomas) every week. Papillomas were
categorized and counted by size (small [0 to 0.2 cm], medium [0.2 to 0.4
cm], large [0.4 cm]). Mice with large growths and lesions were biopsied
weekly for histology and were kept for a maximum of 3 skin biopsies. All
remaining mice were sacrificed 1 year post-DMBA treatment. At the time
of sacrifice, tissues harvested included acetone-painted skin, DMBA/
TPA-painted skin, enlarged lymph nodes, growths, and lesions.
Histopathology analysis. Skin tumors and enlarged lymph nodes
were harvested and fixed in buffered formalin. Tissues were embedded in
paraffin blocks, sectioned, and stained with hematoxylin and eosin (H&E)
by the UNC Histopathology Facility. Tissue sections were examined in a
blinded fashion by the same pathologist (J.N.N., UNC Department of
Pathology and Laboratory Medicine) and classified as papilloma, carci-
noma in situ (CIS), and SCC. The following criteria were used in this
classification. Papillomas consisted of well-differentiated epithelial cells
forming finger-like projections from the epithelial surfaces, often with a
central, connective tissue stalk. Hyperplasia and hyperkeratosis of the
surface epithelium, with retention of nuclei in cells of the keratinized
layers, was common. Carcinoma in situ was identified by an intact base-
ment membrane of the squamous epithelium; however, the epithelium
was thickened and there was failure of normal differentiation. Cells dem-
onstrated pleomorphism, variable nuclear size and shape, abnormal nu-
clear morphology, and abnormal or misplaced mitotic figures near the
epithelial surface. Invasive squamous cell carcinomas had masses of rec-
ognizable squamous epithelial cells, arising from the squamous epithe-
lium, but cells were pleomorphic in size and shape, had variable nuclear
sizes, and had abnormal nuclear morphology (hyperchromatic dark-
staining DNA, coarsely clumped chromatin, large, prominent, often mul-
tiple nucleoli identifiable within the nuclei) and variable nuclear/cyto-
plasmic ratios. Mitoses could be identified and were sometimes atypical.
The squamous epithelial cells demonstrated loss of polarity. Orderly dif-
ferentiation of squamous cells was lost, and large, immature appearing
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cells or cells containing mitotic figures were present within the middle and
superficial layers of epithelium; keratinized cells were present within the
middle or deep layers of epithelium. The basal membrane was breached,
and atypical cells extended into the dermis, sometimes forming sheets or
large masses of cells, occasionally with keratinized cells (keratin pearls) at
the center.
Statistical analysis. For endpoint comparisons, carcinoma, and
H-ras61 mutation incidences (see Tables 2 to 5) were analyzed using
Fisher’s exact test. The Kaplan-Meier (or product-limit) method was used
to estimate the time to carcinoma development, and the log rank test was
used to test for both overall and pairwise differences (see Fig. 2C). To
compare papilloma numbers (Fig. 2A and B), a method known as “re-
sponse features analysis” was used to analyze the repeated measure of the
number of papillomas at each time point (24). This method considers the
growth profile of each animal by calculating the change (slope) in papil-
loma counts over time and is then compared between genotypes using the
nonparametric one-way analysis of variance (Kruskal-Wallis test using
Van der Waerden normal scores). The Wilcoxon two-group method (also
using Van der Waerden normal scores) was then used to test for signifi-
cant (pairwise) differences between genotypes. Reported P values are for
individual tests, unadjusted for multiple comparisons. Statistical analyses
were performed using SAS statistical software, version 9.2 (SAS Institute
Inc., Cary, NC). For comparing immunoblot densitometry values, the
Student t test (two-sided, unpaired) was applied, using the F test to deter-
mine variance (equal or unequal).
Analysis of LMP1 and LMP2 expression by RT-PCR and immuno-
blot analysis. Tissues were homogenized using the TissueLyser II
(Qiagen). Protein was harvested in RIPA buffer followed by immunoblot-
ting. Total RNA was harvested using the RNeasy minikit (Qiagen), and
contaminating genomic DNA was removed with the DNA-free kit (Am-
bion). Reverse transcriptase (RT)-PCR was performed using Brilliant II
quantitative RT-PCR (Stratagene), 100 ng of total RNA and the same
primers used for genotyping for LMP1 and LMP2 detection, and primers
qGAPDH5= (5= TGCACCACCAACTGCTTAGC 3=)/qGAPDH3= (5= GA
GGGGCCATCCACAGTCTT 3=) for GAPDH (glyceraldehyde-3-phos-
phate dehydrogenase).
Immunohistochemistry staining. Paraffin-embedded sections were
stained for phospho-Stat3 (Tyr705) according to the manufacturer’s rec-
ommendation (Cell Signaling). For detection, goat anti-rabbit IgG poly-
horseradish peroxidase (HRP) immunohistochemistry amplification re-
agent (Millipore) was used and developed with enhanced 3,3=-
diaminobenzidine (DAB), counterstained with Mayer’s hematoxylin.
Antibodies. Rabbit anti-pAkt (Ser473 and Thr308), anti-pStat3 /
(Tyr705), and Akt isoform antibody sampler kit (Akt1/2/3, monoclonal
pan-Akt) were purchased from Cell Signaling. Mouse anti-pERK1/2
(Tyr204) (E-4); rabbit anti-ERK2 (C-14), anti-Stat3 / (H-190), and
anti-GAPDH (FL-335) were purchased from Santa Cruz. Rabbit poly-
clonal pan-Akt was purchased from Stressgen. Rat anti-LMP1 (clones
8G3, 1G6, 7E10, and 7G8) was purchased from Ascenion. Rat anti-LMP2
(clone 14B7) was purchased from Abcam.
Analysis of H-ras and K-ras mutations at codons 12, 13, and 61.
Genomic DNA was harvested from homogenized tissue using the DNeasy
kit with RNase treatment (Qiagen). DNA quality was assessed by PCR for
the GAPDH gene using the same primers for RT-PCR. PCR was per-
formed using the PCR 2 master mix (Fermentas), 100 ng of template
DNA, and the primers MH12A1 (5= ATGACAGAATACAAGCTTGT
GGTG 3=)/MH61A2 (5= GGCAAATACACAGAGGAAGCCCTC 3=) for
the H-ras gene (spanning exons 1 to 2). For the K-ras gene, nested PCR
was performed on exons 1 and 2. For exon 1 (containing codons 12 and
13), external primers K-ras exon1-5=-3 (5= TGATAATCTTGTGTGA
GACA 3=)/K-ras exon1-3= (5= ATATCTTTTTCAAAGCGGCT 3=) were
used for the first PCR, and internal primers K-ras exon1-5= (5= CTTGTG
TGAGACATGTTCTAAT 3=)/K-ras exon1-3=-3 (5= CTCTATCGTAGGG
TCGTACT 3=) were used for the second PCR. For exon 2 (containing
codon 61) primers, K-ras exon2-5= (5= AGCTGTTTACATCACCTTGT
3=)/K-ras exon 2-3= (5= GGCATAACAATTAGCAAAGA 3=) were used for
both PCR cycles. For all PCRs, no template served as a negative control.
The PCR products were purified using the QIAquick PCR purification kit
(Qiagen) and sent to sequencing for codons 12, 13, and 61 or digested with
XbaI to confirm the mutation at H-ras61.
RESULTS
LMP1 increases formation and retention of papillomas after tu-
mor promotion and initiation. Chemical carcinogenesis using a
classical regimen of skin painting with a tumor initiator (DMBA)
and promoter (TPA) has been extensively used to study multistage
tumor development (1, 56). The stages of tumor development
involve tumor initiation, promotion to benign papilloma, and
progression to malignant and invasive squamous cell carcinoma.
In this study, initial experiments tested the K14-LMP1 transgenic
mice in the BALB/c mouse strain that were treated with TPA or
treated with DMBA, followed by repeated treatments with TPA.
Papillomas did not develop in any of the treated mice (Table 1).
BALB/c mice are relatively resistant to papilloma formation and
carcinoma development and less than strong effects would not be
apparent (53). A previous study had characterized LMP1 trans-
genic mice in the FVB/N mouse strain that is more susceptible to
initiation/promotion treatment (8, 21, 52, 53). A considerable
number of papillomas developed in all treated mice; however,
despite the high background of papilloma formation in the con-
trol mice, the studies were able to discern that LMP1 had a subtle
effect on numbers of papillomas and cancer development. To de-
crease the influence of strain-specific effects, and determine if the
effects of LMP1 may be more apparent in a less responsive back-
ground than the full FVB/N, the K14-LMP1 BALB/c transgenic
mice were crossed with FVB/N and the F1 offspring were treated
with (i) DMBA one time (1), (ii) DMBA two times (2), (iii)
TPA alone for 20 weeks, or (iv) DMBA 1 followed by TPA for 20
weeks. Few papillomas developed in the mice treated only with
DMBA in LMP1-positive or -negative littermates (Table 1). In the
combined DMBA/TPA treatment study, approximately twice as
FIG 1 Papilloma and carcinoma incidence in DMBA/TPA-treated singly
transgenic K14-LMP1 (A) and K14-LMP2 (B) mice. Small papillomas were
tabulated at 2-week intervals, and carcinomas appeared during the 30-week
interval postcessation of TPA treatment. Plots represent papilloma retention
following cessation of TPA treatment, and arrows indicate the first appearance
of carcinomas. The number of mice per study group (n) is indicated on the
right, and the mean number of small papillomas per mouse is calculated from
mice remaining in the study at each time interval.
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many papillomas developed in the LMP1-positive mice (Fig. 1A).
At the first week postcessation of TPA treatment, the LMP1 mice
had an average of 8.5 papillomas while the negative mice averaged
3.5 papillomas. By 12 weeks postcessation of TPA treatment, pap-
illoma development decreased in the LMP1 mice to 5.6 papillo-
mas and in the negative controls to 2.6 papillomas per mouse
(Table 1). By 28 weeks postcessation of TPA treatment, LMP1
mice had decreased to 2.4 papillomas while the negative mice had
an average of less than 1 papilloma (Fig. 1A). Additionally, 6/59
(10%) LMP1 mice developed carcinomas compared to 2/36 (6%)
negative littermates. These findings confirmed the previous stud-
ies that identified LMP1 to function as a tumor promoter.
LMP2 does not promote papilloma formation and retention.
LMP2 transgenic mice expressing LMP2A, the isoform containing
the N-terminal cytoplasmic signaling domain that is missing from
LMP2B, here referred to simply as LMP2, was obtained on the
CD1 background and was crossed with BALB/c for initial studies.
LMP2-positive and LMP2-negative mice treated with DMBA
alone (1 or 2) or TPA alone did not develop papillomas (Table
1). Papillomas did develop after combined DMBA/TPA treatment
FIG 2 Papilloma and carcinoma incidence in DMBA/TPA-treated singly and doubly transgenic LMP1 and LMP2 mice. Under the common strain background
(50% FVB/N, 25% CD-1, 25% BALB/c), mice were treated with DMBA/TPA and observed for papilloma and carcinoma development. The number of mice per
study group (n) is indicated on the right, and the mean number of small papillomas per mouse is calculated from mice remaining in the study at each time
interval. The number of small papillomas was counted at 2-week intervals for the 20 weeks during TPA treatment (A) and thereafter for 36 weeks post-TPA stop
(B). (A) During TPA treatment, no mice were sacrificed and the data are represented as total mice entered into the study. (B) Postcessation of TPA treatment,
mice were periodically sacrificed and the data are represented as mice remaining in the study. The Wilcoxon two-group method was used to test for significant
differences between genotypes. (C) Kaplan-Meier plot of DMBA/TPA-treated mice depicting carcinoma-free state as a function of time post-TPA start. This
comparison was performed on the subset of mice that completed the 1-year carcinoma study. Log rank test indicate differences between the four genotypes (P  0.01),
and pairwise comparisons indicate significant differences between K14-LMP1/LMP2 compared to nontransgenic controls and K14-LMP2 mice (P0.005 and P0.01,
respectively).
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with approximately equal numbers in LMP2-positive and -nega-
tive mice (Fig. 1B). At the first week postcessation of TPA treat-
ment, both mice had an average of 3.5 papillomas, which de-
creased to 2 to 3 papillomas by 12 weeks postcessation of
treatment (Fig. 1B; Table 1).
To evaluate the effects of LMP2 in the same background as the
LMP1 mice, the LMP2 mice were bred onto a BALB/c background
and then crossed with FVB/N and the 50% FVB/N F1 generation
treated with 100 g DMBA 1 followed by 20 weeks of TPA
treatment. The first week post-TPA. LMP2 mice averaged 4.6 pap-
illomas/mouse while the negative mice averaged 4.3 papillomas/
mouse (data not shown). By week 12, the papilloma numbers
decreased to 3.3 and 3.4 papillomas/mouse, respectively, for pos-
itive and negative mice (Table 1). Several keratoacanthomas de-
veloped in both genotypes, and each genotype developed 2 carci-
nomas. The K14-LMP2 mice have been previously described to
lack a discernible phenotype (17). The data presented here indi-
cate that in this transgenic system, LMP2 does not function as a
tumor initiator or promoter.
The effects of combined expression of LMP1 and LMP2 on
promotion and progression. To evaluate the combined effects of
LMP1 and LMP2, the BALB/c LMP1 mice and CD1 LMP2 mice
were both crossed with FVB/N and the LMP1 and LMP2 F1
were crossed to produce a mixed genotype of approximately 50%
FVB/N. A total of 110 mice genotyped into /, /, /, /
K14-LMP1/LMP2 were treated with DMBA followed by TPA
treatment. Mice were counted for skin growths and lesions every
week, and biopsy samples were taken periodically for histological
analysis. Papillomas started appearing between 6 to 9 weeks dur-
ing TPA treatment (Fig. 2A), but differences were most apparent
at the end of the 20-week TPA treatment (Fig. 2B). During TPA
treatment, the number of mice remained constant and the mean
number of papillomas per mouse was averaged from total mice
entered into the study (Fig. 2A). Post-TPA treatment, mice with
lesions were biopsied or sacrificed and the mean number of pap-
illomas per mouse was averaged from mice remaining in the study
(Fig. 2B). The papillomas were grouped into small (0.2 cm),
medium (0.2 to 0.4 cm), and large (0.4 cm) categories. The
numbers of medium and large papillomas were highly variable
due to loss or biopsy, and only small papillomas could be consis-
tently enumerated and graphically tabulated. During TPA treat-
ment, K14-LMP1 and K14-LMP1/LMP2 mice had higher num-
bers of small papillomas compared to both nontransgenic
controls and K14-LMP2 mice (P  0.004) (Fig. 2A). The K14-
LMP1 mice and the K14-LMP1/LMP2 mice had 8 to 10 papillo-
mas/mouse by the end of TPA treatment while the K14-LMP2
mice and negative mice averaged 3 to 5 papillomas/mouse (Fig.
2A). The numbers of papillomas decreased at the same rate for the
K14-LMP1 and K14/LMP1/LMP2 mice and for the K14-LMP2
mice and controls (Fig. 2B). Importantly, comparison of the K14-
LMP1 and K14-LMP1/LMP2 mice to both nontransgenic controls
and K14-LMP2 mice indicated that they were highly distinct (P 
0.004, during TPA treatment; P  0.001, post-TPA treatment)
(Fig. 2A and B). Additionally, there was no statistical difference
between K14-LMP1/LMP2 and K14-LMP1 mice. These findings
support the previous findings that LMP1 increases the incidence
of papilloma formation, while LMP2 does not increase papilloma
formation or enhance the promotion effects of LMP1.
Carcinoma development was determined by histopathology of
the biopsied samples. Samples diagnosed as carcinomas were tab-
ulated and represented as total number of mice entered into the
study (Table 2) or as the number of mice that completed the study
(Table 3). Based on the total number of mice, the incidence of
carcinoma (SCC/CIS) was higher in K14-LMP1 (21%) and K14-
LMP2 (18%) mice compared to nontransgenic controls (13%).
With the coexpression of both LMP1 and LMP2 in K14-LMP1/
LMP2 mice, carcinoma development was increased (34%) com-
pared to nontransgenic controls (13%, P  0.05). However, ani-
mal numbers decreased during the study due to medical
complications and animal regulations limiting the number of
TABLE 1 Comparison of papilloma and carcinoma incidence in various mouse strains receiving DMBA and/or TPA treatment
Avg no. of papillomas/mouse at wk 12 post-TPA stop (total no. of mice in study)
Mouse strain Treatment LMP1 LMP1
100% BALB/c TPAb 0 (14) 0 (10)
DMBA/TPAc 0 (4) 0 (4)
50% BALB/c, 50% FVB/N DMBAa 1 0 (13) 0 (16)
DMBAa 2 0.66 (12) 0.2 (15)
TPAb 0 (5) 0 (8)
DMBA/TPAc 5.6 (59) 2.6 (36)
LMP2 LMP2
50% BALB/c, 50% CD1 DMBAa 1 0 (9) 0 (12)
DMBAa 2 0 (15) 0 (15)
TPAb 0 (14) 0 (13)
DMBA/TPAc 2.86 (36) 2.06 (34)
50% BALB/c, 50% FVB/N DMBA/TPAc 3.3 (40) 3.4 (31)
LMP1 LMP2 LMP1/2 LMP1/2
25% BALB/c, 25% CD1, 50% FVB/N DMBA/TPAc 6.8 (28) 1.4 (17) 7.9 (35) 2.8 (30)
a 100 g DMBA.
b 10 nmol TPA.
c 100 g/10 nmol DMBA/TPA.
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biopsies; therefore, the data were also analyzed based on the num-
ber of mice that completed the study. K14-LMP1 mice again had
slightly higher numbers of carcinomas (50%) compared to the
nontransgenic controls (33%) or the K14-LMP2 mice (30%).
However, a greater number of carcinomas developed in the K14-
LMP1/LMP2 mice (86%) than in the nontransgenic controls,
which was significant with higher confidence (P  0.01). These
data indicate that the combined expression of LMP1 and LMP2
increases the progression to carcinoma.
Kaplan-Meier analysis of the number of mice that remain car-
cinoma free over time revealed that the time to tumor develop-
ment was not accelerated in the LMP1 or LMP2 transgenic ani-
mals (Fig. 2C). However, this analysis confirmed the differences in
carcinoma incidences between the four genotypes (P  0.01).
Pairwise comparisons indicated significant differences in results
for K14-LMP1/LMP2 mice compared to nontransgenic controls
and K14-LMP2 mice (P  0.005 and P  0.01, respectively), with
borderline significance compared to K14-LMP1 mice (P  0.06).
These analyses reveal that in these studies of initiation, promo-
tion, and progression, LMP1 functions as a tumor promoter to
induce papilloma formation while the combined expression of
LMP1 and LMP2 contributes to tumor progression.
Expression of LMP1 and LMP2 in the K14 lineages. The ex-
pression of LMP1 and LMP2 in the K14 lineages was determined
using immunoblotting and RT-PCR. Expression of LMP1 and
LMP2 protein was determined by immunoblotting using rat
monoclonal antibodies in protein extracts from biopsy samples.
Samples of normal skin, papilloma, CIS, SCC, and ulcers that
result from irritation of skin growths were compared to the levels
of expression in an EBV immortalized (type III latency) lympho-
blastoid cell line (LCL). LMP1 was detected in all samples and
LMP2 expression was detected in most of the sampled tissues. The
more frequent and stronger detection of LMP1 likely reflects dif-
ferences in the antibody reactivities (Fig. 3). The levels of trans-
gene protein expression were variable between samples, reflecting
differing amounts of skin epithelial cells and underlying dermis
within a biopsy sample. In biopsy samples with weak or undetect-
able protein levels, expression was confirmed using RT-PCR.
These findings revealed that LMP1 and LMP2 were expressed in
the normal skin samples, papillomas, and carcinomas of K14-
transgenic mice analyzed in the study.
H-ras61 mutation is induced by DMBA in most papillomas
and carcinomas. Previous studies have determined that treatment
with DMBA results in an activating mutation in codon 61
(A182¡T) of the H-ras gene (36). Treatment with other carcino-
gens such as MNNG and NOR1 induces mutations at other
codons in H-ras, including codons 12 and 13 (39, 40). Mutations
at these codons are typically mutually exclusive, suggesting that
any one activating mutation is sufficient. Biopsy samples were
analyzed for mutation at codon 61 of the H-ras gene. Mutation at
codon 61 introduces an XbaI site, which can be analyzed by XbaI
digestion of the PCR product (spanning exons 1 to 2). A combi-
nation of sequencing and XbaI digestion (Fig. 4) of the PCR prod-
uct identified the mutation in most samples of papillomas and
carcinomas from all genotypes. By sequencing, mutations were
only detected at codon 61, indicating that LMP1 and/or LMP2
expression does not affect other hot spots (codons 12, 13) in the
H-ras gene upon DMBA initiation. However, 2/5 carcinomas
from two K14-LMP1 mice did not have detectable mutations in
codons 12, 13, or 61 (Table 4 and Fig. 4, indicated by an asterisk).
As mutations in K-ras in the absence of a functional H-ras gene
have been identified in DMBA-treated H-ras knockout mice, po-
tential mutations in K-ras were also assessed (12, 28). Sequencing
of the hot spots in exons 1 and 2 of K-ras (codons 12, 13, and 61)
did not identify any mutations that would substitute for the ab-
sence of the H-ras mutation at codon 61 in carcinomas that con-
tained or lacked the H-ras61 mutation (22/25 carcinomas analyzed
for K-ras exon 1 codons 12, 13; 20/25 carcinomas analyzed for
K-ras exon 2 codon 61). Thus, the majority of carcinomas con-
tained the predicted H-ras mutation; however, the absence of mu-
tation in some samples may reflect the ability of LMP1 to activate
common effector signals with H-ras.
To analyze H-ras61 mutations during earlier stages of tumor
progression, papillomas and DMBA/TPA- or vehicle-treated skin
samples from the mice that developed carcinomas were evaluated
(Fig. 4). H-ras61 mutation was not detected in vehicle-treated or
DMBA/TPA-treated skin samples by sequencing or XbaI diges-
tion (Fig. 4). In contrast, H-ras mutation was detected in most
papillomas. These findings indicate that mutation in H-ras is the
initiating event for papilloma induction. Interestingly, one of the
K14-LMP1/LMP2 papillomas lacked the H-ras61 mutation (Fig.
4). Extending the analysis to include a representative papilloma















/ 12 2 2 33
/ 12 5 1 50
/ 10 3 0 30
/ 14 8 4 86c
a The total number of mice entered into the study did not necessarily survive the entire
study before they got a chance to develop a carcinoma. Mice that completed the study
include mice that either survived the entire 1 year study or were sacrificed before the
end of the study but had already developed a diagnosed carcinoma.
b Percentage of mice with carcinomas represented as total number of mice completing
the study.
c P  0.01, statistically significant between K14-LMP1/2 (/) and nontransgenic
(/) or K14-LMP2 (/) mice.
















/ 30 2 2 13
/ 28 5 1 21
/ 17 3 0 18
/ 35 8 4 34c
a The total number of mice entered into the study did not necessarily survive the entire
study before they got a chance to develop a carcinoma. Mice that completed the study
include mice that either survived the entire 1 year study or were sacrificed before the
end of the study but had already developed a diagnosed carcinoma.
b Percentage of mice with carcinomas represented as total number of mice entered into
the study.
c P  0.05, statistically significant between K14-LMP1/2 (/) and nontransgenic
(/) mice.
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from each mouse harvested identified 1/19 K14-LMP1 papilloma
and 2/19 K14-LMP1/LMP2 papillomas that lacked detectable H-
ras61 mutations (Table 5). When comparing all growths (papillo-
mas and carcinomas) that lacked the H-ras61 mutation between
LMP1-expressing (5/53) and LMP1-nonexpressing (0/46) mice,
the difference was borderline significant (P  0.0593). This sug-
gests that in the presence of LMP1, papillomas and carcinomas
from K14-LMP1 or K14-LMP1/LMP2 mice can occasionally de-
velop in the absence of DMBA-induced H-ras61 mutation.
Identification of LMP1- and LMP2-activated signaling path-
ways in carcinomas. LMP1 is known to activate ERK, STAT3, and
Akt, and activation of all three pathways is required for LMP1-
mediated rodent fibroblast transformation (10, 14, 22, 45). LMP2
also activates Akt and is linked to Ras activation (33, 35). To assess
the activation of these pathways by LMP1 and LMP2 in vivo, nor-
mal skin samples and carcinomas were analyzed by immunoblot-
ting using antibodies for phosphorylation activated sites (Fig. 5A).
Quantitation of activated ERK relative to GAPDH indicated that
all the carcinomas had higher levels (2- to 4-fold) of activated
ERK compared to DMBA/TPA-treated skin samples (P 
0.00002) (Fig. 5B). Interestingly, comparisons of carcinomas
showed that the doubly transgenic K14-LMP1/LMP2 carcinoma
samples were significantly more activated than the nontransgenic
controls (P  0.02) (Fig. 5B).
Stat3 is required for both the initiation and promotion of epi-
thelial carcinogenesis by DMBA (6). Activation of Stat3 was de-
termined by blotting for phosphorylation at Tyr705, which is
linked to Stat3 nuclear translocation, and quantitated relative to
GAPDH (Fig. 5B). Carcinomas from all genotypes had increased
levels (1.2- to 2.5-fold) of pStat3 above those of nontransgenic
DMBA/TPA-treated normal skin samples and, on average, the
levels were higher in the carcinoma group than in the DMBA/
TPA-treated normal skin samples (P  0.003) (Fig. 5B). Carcino-
mas from the doubly transgenic mice had significantly higher lev-
els of pStat3 than carcinomas that developed in the control
littermates (P  0.03). Immunohistochemistry detected nuclear
localization of activated Stat3 at Tyr705 in the neoplastic cells of all
carcinomas (Fig. 6). Nonmalignant areas surrounding the carci-
nomas were also analyzed for differences in nuclear
p(Tyr705)Stat3. Activated nuclear p(Tyr705)Stat3 was detected in
all areas of the LMP1 and LMP2 transgenic skin samples but was
not detected in some areas of 2/4 nontransgenic samples (Fig. 6).
These observations confirm that ERK and Stat3 activation occurs
during initiation and promotion and that their activation is most
enhanced in the doubly transgenic group with the highest carci-
noma incidence.
Activation of Akt was also assessed in transgenic skin samples
and carcinomas. Immunoblotting for total Akt using polyclonal
antisera identified two bands, and the slower migrating upper
band was also detected with antibody specific for phosphorylation
at Ser473, which is mediated by the mammalian target of rapamy-
cin complex 2 (mTORC2) (Fig. 7A). Quantitation of the upper
Akt band to the total amount of Akt revealed that higher levels of
activated Akt were detected in the doubly transgenic K14-LMP1/
LMP2 carcinomas compared to the nontransgenic carcinomas
(P  0.03) (Fig. 7B). However, Akt activation was not significantly
higher in the carcinomas from all genotypes compared to the
DMBA/TPA-treated normal skin samples (P  0.08) (Fig. 7B),
suggesting that the effects of LMP1 and LMP2 on Akt may con-
tribute to earlier stages of tumor initiation/promotion, as has been
shown in other DMBA/TPA skin tumorigenesis studies (42, 43).
To further evaluate the effects of LMP1 and LMP2 on Akt
activation, samples where LMP1 and LMP2 were readily detected
by immunoblotting were analyzed using additional antibodies to
distinguish different phospho- and isoform-specific forms of Akt
(Fig. 8). Immunoblotting for total Akt with the rabbit polyclonal
antibody detected three bands in some samples and clearly in two
of the control carcinomas (Fig. 8A). Antibody specific for phos-
pho-Ser473 predominantly detected the middle band (**) and
weakly detected the fastest migrating band (***). The slowest (*)
and fastest (***) migrating bands were equally detected with a
phospho-T308 Akt-specific antibody. This residue is thought to
be phosphorylated through PI3K activation of PDK1. The fastest
migrating (***) band detected with phospho-Thr308 was not de-
FIG 3 Detection of LMP1 and LMP2 expression in carcinomas, papillomas, and normal skin samples. Tissues were confirmed for transgene expression by
RT-PCR and immunoblot analysis. A representative immunoblot analysis for LMP1 and LMP2 is displayed. GAPDH was used as a loading control, and for
LMP1/LMP2 detection controls, an EBV immortalized B cell line (LCL) was used as a positive control and an uninfected B cell line (BJAB) was used as a negative
control. Pap, papillomas; NS, nonspecific band.
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tected in the control carcinomas but was detected in 1/4 LMP1
carcinomas, 2/2 LMP2 carcinomas, and 3/3 LMP1/LMP2
carcinoma samples (Fig. 8A).
The lysates were also analyzed using antibodies to peptides
specific for the Akt1, -2, and -3 isoforms to screen for possible
differences in isoform expression that could account for pheno-
typic differences (Fig. 8B). The C2C12 mouse myoblast cell line
was included as a positive control for all three isoforms. Akt1 and
Akt2 antibodies detected the ** band and Akt2 antibody also de-
tected the *** band. Additionally, Akt1 antibody strongly detected
a smaller band of approximately 48 kDa previously described to be
a caspase cleavage product (20, 27). The isotype-specific antibod-
ies have been shown to not cross-react; thus the detection of the **
band by both antibodies perhaps indicates that both forms mi-
FIG 4 Detection of H-ras61mutation in tissues from DMBA/TPA-treated and vehicle control-treated mice. H-ras61 mutation was detected by XbaI digestion (a
site introduced through mutation at codon 61) of a PCR product spanning exons 1 and 2. Tissues screened include carcinomas, papillomas, tails, and normal skin.
Tails were not treated with carcinogens or vehicle and served as controls for any basal levels of spontaneous H-ras61 mutations. Samples where there were no
detectable H-ras61 mutations are indicated (*) and were confirmed by sequencing.


















/ 4 0/4 0/4
/ 6 2/4 2/5
/ 3 0/2 0/6
/ 12 0/9 0/10
a Samples were prescreened for genomic DNA quality by PCR for GAPDH followed by
analysis for H-ras61.

















/ 24 0/24 0/24
/ 19 1/19 1/19
/ 12 0/12 0/12
/ 19 2/19 2/19
a Samples were prescreened for genomic DNA quality by PCR for GAPDH followed by
analysis for H-ras61.
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FIG 5 Immunoblot analysis of normal skin samples and carcinomas for activated ERK and Stat3 in DMBA/TPA-treated mice. (A) Activation was detected with
phospho-specific antibodies to ERK1/2 (Y204) and Stat3 (Y705). GAPDH was used as a loading control. (B) ERK and Stat3 activation was normalized to GAPDH
and plotted for comparison. The same DMBA/TPA skin samples were run on each gel, allowing for an assessment of variation between gels. The distribution of
ERK and Stat3 activation is displayed for each genotype, and the mean value is indicated by a solid line. Student’s t test was used to compare between tissue groups
and transgenic samples relative to the control. Comparisons with P values of 0.05 are displayed.
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grate identically. The Akt3 antibody faintly detected multiple
bands on long exposure, suggesting that Akt3 is not expressed.
Analysis of the vehicle control-treated skin samples identified only
Akt2, the cleaved form of Akt1, and no Akt3 (data not shown).
These findings indicate that Akt2 is the predominant isoform of
Akt that is activated in this model.
DISCUSSION
LMP1 and LMP2 are expressed in NPC and other EBV-associated
tumors and have potent effects on cell growth and transformation
(38, 54, 55). The DMBA/TPA painting regimen has been a critical
tool to determine the contribution of chemical carcinogens and
oncogene activation in a model of multistage carcinogenesis that
distinguishes effects on tumor initiation, promotion, and progres-
sion (1, 56). In combination with transgenic mice, the approach
has revealed distinct effects of the human papillomavirus (HPV)
E7, E6, and E5 on papilloma promotion, carcinoma progression,
and both stages, respectively (25, 47). Animal models are not
available for HPV, and these distinct functional contributions
could not have been identified using in vitro culture systems. Sim-
ilarly, EBV also lacks a mouse model and the study of its effects on
epithelial cell growth is dependent on cell culture systems. How-
ever, interesting transgenic mouse models have revealed a contri-
bution of LMP1 to lymphoma development when expressed in B
cells and to papilloma and carcinoma development when ex-
pressed using polyoma or EBV promoters (8, 13, 44, 48, 51, 52).
This study shows that LMP1 but not LMP2 functions as a tumor
promoter when expressed specifically in basal epithelial cells. The
K14-LMP2 mice have been previously shown to lack any obvious
pathological phenotype (17), and in this current study, LMP2 did
not contribute to initiation or promotion but importantly did
contribute to cancer progression.
Distinct inbred and outbred strains have highly variable re-
sponses to initiation and promotion. In this study, most experi-
ments used an F1 hybrid mouse that was 50% FVB/N. Impor-
tantly, the control mice in all experiments had very consistent low
levels of papilloma formation, with 2 to 3 papillomas at 12 weeks
post-TPA. Regardless of the background, the LMP1-positive mice
developed 2 to 3 times as many papillomas as control mice and the
papillomas had prolonged persistence. This effect was apparent
both in the LMP1-positive transgenic mice and in the doubly pos-
itive LMP1/LMP2 mice. In the multistep carcinoma model, treat-
ment with DMBA results in mutation of H-ras while TPA is
thought to contribute possibly through the activation of Stat3 (6,
36). Activation of epidermal growth factor receptor (EGFR) sig-
naling has also been identified as an important component in the
development of carcinomas, which are distinguished from normal
skin by elevated activation of ERK, Stat3, and Akt (5, 19, 43). As
LMP1 is known to activate ERK, Stat3, and Akt and to induce
constitutively phosphorylated EGFR, it might be expected that
FIG 6 Immunohistochemistry for pStat3 (Y705) in carcinomas and surrounding epithelia of DMBA/TPA-treated mice. The number of samples showing a
similar detection to the representative field is indicated. Scale bar, 20 m.
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expression of LMP1 would have major effects on both papilloma
development and progression to carcinoma (9, 10, 14, 15, 22, 45).
However, the effects of LMP1, in general, on tumor promotion
and induction of papilloma formation were relatively subtle. In-
terestingly, ras mutation was lacking in 2/5 LMP1 carcinomas, in
1/19 LMP1 papillomas, and in 2/19 LMP1/LMP2 papillomas. The
absence of ras mutation in this small subset of carcinomas and
papillomas may indicate that the effects of LMP1, potentially on
FIG 7 Immunoblot analysis of normal skin samples and carcinomas for activated Akt in DMBA/TPA-treated mice. (A) Activated Akt was detected using
phospho-specific antibodies to Ser-473 and as the upper species of the doublet band detected with the polyclonal total Akt antibody. The percentage of Akt
activation was calculated from the average of three exposures of the total Akt immunoblot (activated band/sum of activated and nonactivated bands). One
representative exposure from each gel is shown. (B) Percentage of Akt activation is plotted for each sample, and the mean value for each genotype is indicated by
a solid line. The same DMBA/TPA skin samples were run on each gel, allowing for an assessment of variation between gels. Student’s t test was used to compare
between tissue groups and transgenic samples relative to the control. An asterisk denotes significant P values of 0.05.
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ERK and Stat3, can sometimes substitute for constitutively acti-
vated Ras. In EBV-associated tumors, including NPC, ras muta-
tion does not occur. However, ras pathways are activated and one
contributing factor is the lack of RASSF1A expression, a ras-bind-
ing protein that acts as a tumor suppressor (16, 23).
It has been previously shown that LMP2 induces Akt activation
and can block epithelial cell differentiation, and some similarities
between the Ig-LMP2 transgenic and activated Ras transgenic
mice suggested that LMP2 can directly activate the Ras/PI3K/Akt
pathway to mediate B cell survival (33, 35, 41). However, when
FIG 8 Immunoblot analysis of highly expressing carcinomas for activated pAkt (S473, T308) and Akt isoforms. (A) Various modifications of Akt (*, **, ***, slow,
medium, and fast migrating, respectively) were detected with phospho-specific antibodies (pAkt-S473 and -T308) and a polyclonal pan-Akt antibody. (B) The
expression of Akt isoforms was detected using isoform-specific peptide antibodies. The corresponding position of the various Akt modification bands is indicated
with asterisks (*, **, ***). A cleaved Akt1 product was also detected and is indicated by an enclosed circle ( ). GAPDH was used as a loading control.
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expressed in epithelial cells, differences in skin development or
pathology were not detected in the K14-LMP2A transgenic mice
(17). Akt signaling contributes to both tumor promotion and pro-
gression during TPA treatment and constitutively activated Akt
results in enhanced papilloma formation (19, 42, 43). The data in
this study show that even with the treatment of DMBA and TPA,
LMP2 did not enhance tumor promotion, as evidenced by the lack
of increased or sustained papilloma development. However, the
expression of LMP2 in combination with LMP1 did significantly
increase carcinoma development (Table 2).
To discern how LMP1 and LMP2 affect cell growth in this
model, the activation of the signaling pathways that are known to
contribute to promotion and progression was assessed. In confir-
mation of previous studies, the carcinomas were distinguished
from normal skin samples with constitutive, elevated ERK and
Stat3 activation, which was highest in the doubly transgenic K14-
LMP1/LMP2 carcinomas (Fig. 5) (43). It is known that both
LMP1 and LMP2 can activate Akt; however, distinct outcomes of
activation have been identified (10, 22, 33, 41, 45, 46). For exam-
ple, only LMP2 induces -catenin nuclear translocation in an Akt-
dependent manner (33). Analysis of Akt activation in the carcino-
mas identified multiple bands that had distinct reactivities using
phospho-specific antibodies. The predominant forms of Akt that
were detected were Akt2 and a cleaved form of Akt1. The pattern
of phosphorylation was complex; however, a unique band identi-
fied with Thr308-specific pAkt antibody was detected predomi-
nantly in the transgenic carcinomas that expressed LMP2. How-
ever, the same pathways, overall, were activated in carcinomas
that developed in control and transgenic mice. This suggests that
the contribution of EBV and its oncogenes, LMP1 and LMP2, to
tumor development is likely the enhanced activation of pathways
that can also be sporadically activated in the absence of LMP1 or
LMP2 and lead to tumor development. This is similar to EBV-
associated cancers in vivo where pathways that are activated by
LMP1 are also activated in the less prevalent EBV-negative forms
of the cancers (32, 49).
Both LMP1 and LMP2 are expressed in NPC, and their coop-
eration in this carcinogenesis model reveals their combined onco-
genic potential in causing disease. As in the carcinogenesis model,
genetic changes are likely required in vivo, in addition to LMP1
and LMP2 expression, to result in carcinoma formation, while the
signaling events initiated by LMP1 and LMP2 likely provide the
critical signals needed for tumor promotion and progression.
The further characterization of the specific effects of LMP1 and
LMP2 may identify essential pathways and interactions that can be
specifically targeted to develop therapeutic strategies against EBV-
associated cancers.
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